SNAIL-MEDIATED SIGNALING IN HUMAN PROSTATE CANCER

人类前列腺癌中蜗牛介导的信号传导

基本信息

  • 批准号:
    8166161
  • 负责人:
  • 金额:
    $ 27.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-07-01 至 2011-06-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Epithelial-mesenchymal transition (EMT) occurs during normal embryonic development and epithelial tumor progression. Several factors associated with EMT contribute to motility, invasion, and angiogenesis, and may be important therapeutic targets for prostate cancer metastasis. Understanding the factors that contribute to EMT and prostate cancer metastasis is crucial for development of cancer therapies. For example, Snail transcription factor has been identified as an important factor that can induce EMT in breast and colon cancer. However, the role of EMT in prostate cancer is not well defined and good EMT models are lacking. Recently we have established an EMT model for prostate cancer progression using the ARCaP cell model overexpressing Snail. The goal of this proposal is to study the role of Snail transcription factor in prostate cancer progression and metastasis. We have found that Snail-induced EMT in prostate cancer cells involves reactive oxygen species (ROS) and receptor activator of NFkB (RANKL), two factors that are important in cancer disease progression and bone metastatic lesions, respectively. This proposal will elucidate the biological significance of Snail, with emphasis of its role in prostate cancer bone metastasis. In addition, we will characterize the signaling pathway of Snail-induced EMT, and finally examine the effect of antagonizing Snail expression on tumor aggressiveness in vitro and in vivo. We believe these studies will identify Snail as an attractive therapeutic target not only for EMT during primary tumor progression but also for bone metastatic lesions at the secondary site.
这个子项目是众多研究子项目之一

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Valerie Odero-Marah其他文献

Valerie Odero-Marah的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Valerie Odero-Marah', 18)}}的其他基金

HMGA2 mediates resistance to therapy in prostate cancer
HMGA2 介导前列腺癌治疗耐药
  • 批准号:
    10622747
  • 财政年份:
    2023
  • 资助金额:
    $ 27.24万
  • 项目类别:
RCMI@Morgan: Center for Urban Health Disparities Research and Innovation
RCMI@摩根:城市健康差异研究与创新中心
  • 批准号:
    10372112
  • 财政年份:
    2019
  • 资助金额:
    $ 27.24万
  • 项目类别:
RCMI@Morgan: Center for Urban Health Disparities Research and Innovation
RCMI@摩根:城市健康差异研究与创新中心
  • 批准号:
    10671920
  • 财政年份:
    2019
  • 资助金额:
    $ 27.24万
  • 项目类别:
RCMI@Morgan: Center for Urban Health Disparities Research and Innovation
RCMI@摩根:城市健康差异研究与创新中心
  • 批准号:
    10452009
  • 财政年份:
    2019
  • 资助金额:
    $ 27.24万
  • 项目类别:
RCMI@Morgan: Center for Urban Health Disparities Research and Innovation
RCMI@摩根:城市健康差异研究与创新中心
  • 批准号:
    10113369
  • 财政年份:
    2019
  • 资助金额:
    $ 27.24万
  • 项目类别:
RCMI@Morgan: Center for Urban Health Disparities Research and Innovation
RCMI@摩根:城市健康差异研究与创新中心
  • 批准号:
    10599734
  • 财政年份:
    2019
  • 资助金额:
    $ 27.24万
  • 项目类别:
The Role of Snail Signaling in Prostate Cancer Metastasis
蜗牛信号在前列腺癌转移中的作用
  • 批准号:
    8495467
  • 财政年份:
    2013
  • 资助金额:
    $ 27.24万
  • 项目类别:
Snail Signalling in Human Prostate Cancer
人类前列腺癌中的蜗牛信号传导
  • 批准号:
    8544046
  • 财政年份:
    2012
  • 资助金额:
    $ 27.24万
  • 项目类别:
SNAIL-MEDIATED SIGNALING IN HUMAN PROSTATE CANCER
人类前列腺癌中蜗牛介导的信号传导
  • 批准号:
    8357123
  • 财政年份:
    2011
  • 资助金额:
    $ 27.24万
  • 项目类别:
SNAIL-MEDIATED SIGNALING IN HUMAN PROSTATE CANCER
人类前列腺癌中蜗牛介导的信号传导
  • 批准号:
    7959171
  • 财政年份:
    2009
  • 资助金额:
    $ 27.24万
  • 项目类别:

相似海外基金

Intelligent Breast Cancer DiagnOsis and MonItoring Therapeutic Response Training Network (CanDoIt)
智能乳腺癌诊断和监测治疗反应训练网络(CanDoIt)
  • 批准号:
    EP/Y03693X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 27.24万
  • 项目类别:
    Research Grant
From single-cell transcriptomic to single-cell fluxomic: characterising metabolic dysregulations for breast cancer subtype classification
从单细胞转录组到单细胞通量组:表征乳腺癌亚型分类的代谢失调
  • 批准号:
    EP/Y001613/1
  • 财政年份:
    2024
  • 资助金额:
    $ 27.24万
  • 项目类别:
    Research Grant
Quad negative breast cancerに対する新たなプレシジョン・メディシン治療戦略
四阴性乳腺癌精准医学治疗新策略
  • 批准号:
    24K11748
  • 财政年份:
    2024
  • 资助金额:
    $ 27.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Preclinical validation of synthetic biomolecules to treat Breast Cancer from AI-enabled discovery of novel lncRNA therapeutic targets.
通过人工智能发现新型 lncRNA 治疗靶点,对合成生物分子治疗乳腺癌进行临床前验证。
  • 批准号:
    10110204
  • 财政年份:
    2024
  • 资助金额:
    $ 27.24万
  • 项目类别:
    Launchpad
ESR1 mutation profiling identifies potential drivers of metastatic breast cancer
ESR1 突变分析确定了转移性乳腺癌的潜在驱动因素
  • 批准号:
    MR/X018199/1
  • 财政年份:
    2024
  • 资助金额:
    $ 27.24万
  • 项目类别:
    Research Grant
Spatial-BrTME: Multicellular spatial dynamics of immunotherapy response in breast cancer
Spatial-BrTME:乳腺癌免疫治疗反应的多细胞空间动力学
  • 批准号:
    EP/Y014995/1
  • 财政年份:
    2024
  • 资助金额:
    $ 27.24万
  • 项目类别:
    Research Grant
Enhancements to design and testing of Body Aspect's breast volume measurement software
Body Aspect 乳房体积测量软件的设计和测试得到增强
  • 批准号:
    10074432
  • 财政年份:
    2023
  • 资助金额:
    $ 27.24万
  • 项目类别:
    Collaborative R&D
Decoding the impact of single cell mutational processes in triple negative breast cancer and high grade serous ovarian cancer
解读单细胞突变过程对三阴性乳腺癌和高级别浆液性卵巢癌的影响
  • 批准号:
    477662
  • 财政年份:
    2023
  • 资助金额:
    $ 27.24万
  • 项目类别:
    Operating Grants
225Ac-labeled anti-nectin-4 radioimmunoconjugate with/without immune checkpoint blockage in triple negative breast cancer.
225Ac 标记的抗 nectin-4 放射免疫缀合物,有/没有免疫检查点阻断治疗三阴性乳腺癌。
  • 批准号:
    488261
  • 财政年份:
    2023
  • 资助金额:
    $ 27.24万
  • 项目类别:
    Operating Grants
Identifying the molecular and environmental factors involved in promoting escape from breast cancer dormancy.
确定参与促进乳腺癌休眠逃逸的分子和环境因素。
  • 批准号:
    488246
  • 财政年份:
    2023
  • 资助金额:
    $ 27.24万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了